Study guide

16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

Key Takeaways Explain This Topic AI

Continuous IV epoprostenol for pulmonary arterial hypertension has a half-life of about 6 minutes, so an interrupted infusion must be restarted immediately and the line must never be flushed.

Insulin pumps hold only rapid-acting insulin; when a pump is stopped for DKA, altered mental status or imaging, IV or subcutaneous basal insulin must start promptly to prevent ketoacidosis.

Abrupt intrathecal baclofen withdrawal causes itching, fever, rebound spasticity, rhabdomyolysis and death, and the priority is restoring intrathecal delivery.

Intranasal atomizer doses should use the most concentrated product, with no more than about 1 mL per nostril, divided between both nostrils.

A metered-dose inhaler needs a slow, deep breath with a spacer, while a dry powder inhaler needs a fast, forceful breath and must never be shaken or exhaled into.

Last updated: October 2026

16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

Note

Exam scope: 2025 outline subtopics 1B5 (Infusion Devices) and 1B6 (Medication Delivery Devices, e.g., inhalers, EpiPens, atomizers), with counseling skills from 2C9. Smart pump drug libraries and dose error reduction software are covered with medication safety in Section 14.1.

Infusion Devices in the ED

Device Typical use Failure modes to anticipate

Large-volume smart pump Most continuous infusions and intermittent doses Programming outside the drug library, wrong concentration chosen, secondary (piggyback) infusion running from the wrong bag

Syringe pump Small volumes of concentrated drugs, neonatal and pediatric infusions Delay before flow starts, siphoning if mounted above the patient, unintended boluses when moved or when a clamp is released

Rapid infuser with warmer Massive transfusion and large-volume resuscitation Air embolism, hypothermia if warming fails, hypocalcemia from citrate

Patient-controlled analgesia (PCA) pump Opioid analgesia for admitted patients "PCA by proxy" when family members press the button; a basal infusion in opioid-naive patients raises the risk of respiratory depression

Elastomeric (balloon) pump Outpatient antibiotics, continuous nerve blocks Flow changes with temperature and fill volume; cannot be programmed

Gravity infusion with a roller clamp Fluids when pumps are scarce Inaccurate rates and free flow; unsuitable for high-alert drugs

Two habits prevent many infusion errors. First, trace each line from the bag to the patient before starting or changing any infusion. Second, confirm that the secondary bag hangs above the primary and that clamps are open only where intended. Pump-EHR integration, where orders send rates directly to the pump, removes keystroke errors but does not replace the bedside check.

  • Patient-Owned Devices That Must Not Be Interrupted
  • Pulmonary Arterial Hypertension Infusions

Continuous IV epoprostenol has a half-life of about 6 minutes . If the pump fails or the catheter becomes dislodged, pulmonary pressures rebound within minutes and the patient can develop right ventricular failure and cardiac arrest.

Restart the infusion immediately at the home rate, through a peripheral IV if the central line is unusable. Ask the patient or caregiver for their backup supplies and pump.

Never flush the epoprostenol line and never draw blood from it, because flushing delivers a bolus.

Contact the patient's pulmonary hypertension center and specialty pharmacy.

Subcutaneous or IV treprostinil has a longer half-life (about 4 hours), which allows a little more time but still requires prompt restoration.

Insulin Pumps and Automated Insulin Delivery

The 2026 ADA Standards of Care support continuing insulin pumps, including automated insulin delivery systems, in hospitalized patients when it is clinically appropriate and the institution has a protocol, supplies and trained staff. Personal continuous glucose monitors may also continue, with point-of-care glucose checks to confirm values before insulin dosing or hypoglycemia treatment.

Stop or remove the pump when the patient has altered mental status, DKA or HHS, critical illness, or will undergo MRI or certain procedures , or when the patient cannot manage the device. Because pumps deliver only rapid-acting insulin, start IV insulin or give subcutaneous basal insulin as the pump is stopped . With no insulin depot, ketoacidosis can begin within a few hours. Pump malfunction, such as a kinked cannula or empty reservoir, is itself a common trigger for DKA.

Intrathecal Baclofen Pumps

Intrathecal baclofen labeling carries a boxed warning about abrupt discontinuation , which can be fatal. Withdrawal follows a low reservoir, catheter kink or disconnection, or pump failure. Signs include:

  • Pruritus without a rash (often early)
  • Return of spasticity, high fever and altered mental status
  • Autonomic instability, rhabdomyolysis, seizures and multiorgan failure

Management:

Restore intrathecal delivery as quickly as possible; the patient's pump team or neurosurgery can interrogate and refill the pump.

Give high-dose oral or enteral baclofen , which is absorbed unpredictably and works slowly.

Give IV benzodiazepines for spasticity and agitation, with cooling and supportive care.

Intrathecal opioid and ziconotide pumps raise similar problems, and accidental overdose during refills is a known hazard.

  • Medication Delivery Devices and Counseling
  • Inhaled Devices

Device Inhalation technique Practical points

Pressurized metered-dose inhaler (MDI) Shake, exhale away from the device, seal lips, start a slow, deep breath (3 to 5 seconds) as you press, then hold the breath about 10 seconds Use a valved holding chamber (spacer), with a mask for young children; prime new inhalers

Dry powder inhaler (DPI) Load the dose, exhale away from the device, then inhale quickly and forcefully Do not shake; do not breathe into the device; needs enough inspiratory flow, so it is a poor choice during a severe attack or for young children

Soft mist inhaler Slow, deep breath while pressing Assemble and prime the cartridge before first use

Nebulizer (jet or mesh) Normal breathing through a mouthpiece or mask Takes longer; useful when the patient cannot coordinate or is very breathless

An MDI with a spacer works as well as a nebulizer for most acute asthma in adults and children. Four to eight puffs of albuterol (90 mcg each) is commonly treated as equivalent to a 2.5 mg nebulized dose. Before discharge after an asthma exacerbation, check technique and make sure the patient leaves with an inhaled corticosteroid-containing controller (Section 7.2).

Epinephrine Products for Anaphylaxis

Autoinjectors: inject into the outer thigh, through clothing if needed, and hold for the time stated on the device (about 3 seconds for EpiPen). Call emergency services, and give a second dose after 5 to 15 minutes if symptoms persist or return. Weight-based device strengths are listed in Section 7.3.

Nasal epinephrine (neffy): 2 mg for patients 30 kg or more, 1 mg for those 15 to under 30 kg. If symptoms do not improve, a second dose is given with a new device in the same nostril after 5 minutes.

Prescribe two devices , check expiration dates, avoid temperature extremes, and teach caregivers and schools.

Intranasal Atomizers

A mucosal atomization device turns a liquid dose into a fine mist that is absorbed through the nasal mucosa, avoiding a needle stick.

Use the most concentrated product : midazolam 5 mg/mL, fentanyl 50 mcg/mL, ketamine 50 or 100 mg/mL.

Give no more than about 1 mL per nostril , ideally 0.2 to 0.5 mL, and split the dose between both nostrils .

Add about 0.1 mL for the device's dead space.

Blood, mucus or vasoconstrictors reduce absorption.

  • Indication Typical intranasal dose
  • Seizure rescue (midazolam) 0.2 mg/kg (maximum 10 mg)
  • Pediatric pain (fentanyl) 1.5 mcg/kg (maximum 100 mcg per dose)
  • Opioid overdose (naloxone) Commercial 4 mg nasal spray, or 2 mg by atomizer

Worked example: a 20-kg child having a seizure needs midazolam 0.2 mg/kg = 4 mg. With 5 mg/mL midazolam, the volume is 0.8 mL, given as 0.4 mL in each nostril .

Ready-to-Use Rescue Products

Opioid overdose: naloxone 4 mg nasal spray (sold over the counter since 2023), naloxone 8 mg nasal spray, and nalmefene nasal spray and autoinjector. Nalmefene lasts longer than naloxone and can cause prolonged withdrawal in people physically dependent on opioids.

Severe hypoglycemia: nasal glucagon 3 mg, ready-to-use glucagon autoinjectors and prefilled syringes, and dasiglucagon.

Seizure clusters: rectal diazepam gel, diazepam nasal spray, and midazolam nasal spray (labeled for patients 12 years and older).

Injectables, Pens and Patches

Insulin pens: prime 2 units before each dose and hold the needle in the skin for about 10 seconds. Never share a pen between patients, even with a new needle , because blood can flow back into the cartridge.

Enoxaparin prefilled syringes: do not expel the air bubble from fixed-dose syringes, inject into the abdomen, rotate sites and do not rub.

Weekly methotrexate: confirm the weekly schedule at every counseling contact, because daily dosing errors have been fatal.

Fentanyl patches: heat from fever, heating pads or hot baths increases absorption. Remove the old patch, fold used patches sticky sides together before disposal, and keep them away from children.

Metal-backed patches (some nicotine, clonidine, testosterone and other products) can cause burns during MRI and should be removed beforehand.

Nitroglycerin patches need a daily patch-free interval of 10 to 12 hours to prevent tolerance.

Counseling That Works

Use teach-back : ask the patient to show or explain how they will use the device, rather than asking "Do you have any questions?" Demonstrate with a trainer device, give written instructions with pictures in the patient's preferred language, and include caregivers. Section 18.3 covers health literacy and access barriers.